基于医院的心力衰竭质量改进干预:系统综述
该系统综述检索截至2017年2月的随机试验,评估住院心衰质量改进干预对诊疗过程和临床结局的影响。共纳入14项多维度干预的随机对照试验,定性合成显示多数过程指标和临床结局无一致效应,证据质量极低至中等。
要点
- 住院心衰质量改进干预对多数诊疗过程指标和临床结局无一致效应。
- 部分试验显示干预组ACEI和β受体阻滞剂使用有升高趋势,但出院带药无效应。
- 证据质量极低至中等,未来研究可能影响现有估计。
核心结论
- 基于医院的HF质量改进干预随机试验未显示对多数诊疗过程指标和临床结局的一致效应。
- 预设主要和关键次要结局的总体证据质量极低至中等,未来研究可能影响这些估计。
研究设计与样本
- 系统综述,结构化检索截至2017年2月评估住院HF质量改进干预的随机试验。
- 从3615条记录中纳入14项多维度干预的随机对照试验,因异质性大进行定性合成。
主要发现
- 一项试验(n=429)中干预组较对照组住院期间ACEI使用有升高趋势(57.9% vs 40.0%),β受体阻滞剂使用有升高趋势(46.7% vs 10.2%)。
- 五项试验(n=78 727)显示干预对出院时ACEI或ARB使用无效应。
- 三项试验(n=89 660)报告干预对出院时β受体阻滞剂使用无效应。
- 两项试验(n=419)显示干预组出院后90天内再入院有降低趋势。
- 质量改进干预对30天全因死亡率、住院时长和患者层面健康相关生活质量无一致效应。
临床怎么用
- 现有证据不支持医院HF质量改进干预能一致改善多数诊疗过程指标和临床结局。
- 临床决策时应考虑证据质量极低至中等,未来研究可能改变效应估计。
局限性
- 因研究间异质性大,仅进行定性合成而未做定量合并。
- 预设主要和关键次要结局的总体证据质量极低至中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the direction and magnitude of effect and quality of evidence for hospital-based heart failure (HF) quality improvement interventions on process of care measures and clinical outcomes among patients with acute HF. REVIEW METHODS: We performed a structured search to identify relevant randomised trials evaluating the effect of in-hospital quality improvement interventions for patients hospitalised with HF through February 2017. Studies were independently reviewed in duplicate for key characteristics, outcomes were summarised and a qualitative synthesis was performed due to substantial heterogeneity. RESULTS: From 3615 records, 14 randomised controlled trials were identified for inclusion with multifaceted interventions. There was a trend towards higher in-hospital use of ACE inhibitors (ACE-I; 57.9%vs40.0%) and beta-blockers (BBs; 46.7%vs10.2%) in the intervention than the comparator in one trial (n=429 participants). Five trials (n=78 727 participants) demonstrated no effect of the intervention on use of ACE-I or angiotensin receptor blocker at discharge. Three trials (n=89 660 participants) reported no effect on use of BB at discharge. Two trials (n=419 participants) demonstrated a trend towards lower hospital readmission up to 90 days after discharge. There was no consistent effect of the quality improvement intervention on 30-day all-cause mortality, hospital length of stay and patient-level health-related quality of life. CONCLUSIONS: Randomised trials of hospital-based HF quality improvement interventions do not show a consistent effect on most process of care measures and clinical outcomes. The overall quality of evidence for the prespecified primary and key secondary outcomes was very low to moderate, suggesting that future research will likely influence these estimates. TRIAL REGISTRATION NUMBER: CRD42016049545.
引用
- Agarwal A, Bahiru E, Yoo SGK, et al. Hospital-based quality improvement interventions for patients with heart failure: a systematic review. Heart. 2019. PMID: 30700515. doi:10.1136/heartjnl-2018-314129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。